Evidence map›Paper›PMID 25324513›Full record

ArticleJournal of applied physiology (Bethesda, Md. : 1985)2014

Impact of familial hypertrophic cardiomyopathy-linked mutations in the NH2 terminus of the RLC on β-myosin cross-bridge mechanics.

Gerrie P Farman, Priya Muthu, Katarzyna Kazmierczak, Danuta Szczesna-Cordary, Jeffrey R Moore

Open access · greenAbstract read
In one paragraph

Article in Journal of applied physiology (Bethesda, Md. : 1985), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Understanding the molecular basis of cardiomyopathy.American journal of physiology. Heart and circulatory physiology · 2022
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gerrie P FarmanDepartment of Physiology and Biophysics, Boston University, Boston, Massachusetts; and.
Priya MuthuDepartment of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida.
Katarzyna KazmierczakDepartment of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida.
Danuta Szczesna-CordaryDepartment of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida.
Jeffrey R MooreDepartment of Physiology and Biophysics, Boston University, Boston, Massachusetts; and jxmoore@bu.edu.
University of Miami · USBoston University · US

Funding

Functional Consequences of FHC-linked RLC Mutations.R01HL071778 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SZCZESNA-CORDARY, DANUTA · 2003 to 2012
$3.5M
Molecular Mechanics of Mutant Cardiac MyosinR01HL077280 · NHLBI · UNIVERSITY OF MASSACHUSETTS LOWELL · PI MOORE, JEFFREY R · 2005 to 2014
$3.3M
Myosin ELC, a novel therapeutic target for FHCR01HL108343 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SZCZESNA-CORDARY, DANUTA · 2012 to 2015
$1.5M
NHLBI NIH HHS HL-071778NHLBI NIH HHS HL-077280NHLBI NIH HHS HL-108343NHLBI NIH HHS R01 HL071778NHLBI NIH HHS R01 HL077280NHLBI NIH HHS R01 HL108343
6 · The paper itself

Abstract

Familial hypertrophic cardiomyopathy (HCM) is associated with mutations in sarcomeric proteins, including the myosin regulatory light chain (RLC). Here we studied the impact of three HCM mutations located in the NH2 terminus of the RLC on the molecular mechanism of β-myosin heavy chain (MHC) cross-bridge mechanics using the in vitro motility assay. To generate mutant β-myosin, native RLC was depleted from porcine cardiac MHC and reconstituted with mutant (A13T, F18L, and E22K) or wild-type (WT) human cardiac RLC. We characterized the mutant myosin force and motion generation capability in the presence of a frictional load. Compared with WT, all three mutants exhibited reductions in maximal actin filament velocity when tested under low or no frictional load. The actin-activated ATPase showed no significant difference between WT and HCM-mutant-reconstituted myosins. The decrease in velocity has been attributed to a significantly increased duty cycle, as was measured by the dependence of actin sliding velocity on myosin surface density, for all three mutant myosins. These results demonstrate a mutation-induced alteration in acto-myosin interactions that may contribute to the pathogenesis of HCM.

Indexed as

MutationMyocardial ContractionAnimalsCardiac MyosinsCardiomyopathy, Hypertrophic, FamilialGenetic Predisposition to DiseaseHumansKineticsMyocytes, CardiacMyosin Heavy ChainsMyosin Light ChainsPhenotypeProtein BindingProtein Interaction Domains and MotifsRecombinant ProteinsSwineCardiac MyosinsMyosin Heavy ChainsMyosin Light ChainsRecombinant Proteinscardiac ventricular myosinhypertrophic cardiomyopathyin vitro motilitymyosin regulatory light chain

Identifiers

PMID25324513
PMCPMC4269682
OpenAlexW2313988373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.